Overview

Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Molgramostim
Rituximab
Sargramostim